Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lenvima
Pharma
Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Takeda made pipeline cuts in Q3. Innovent reported a head-to-head win against semaglutide. Roche inked a respiratory bispecific deal. And more.
Angus Liu
Oct 31, 2025 8:20am
Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type
Oct 29, 2025 11:32am
Merck, Eisai combo misses survival goal in GI cancer trial
Jan 24, 2025 10:26am
Daiichi, Eisai, Granules—Fierce Pharma Asia
Sep 20, 2024 10:16am
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
BMS, China reimbursement update, CAR-T hold—Fierce Pharma Asia
Dec 15, 2023 5:15am
